Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase...

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Current Alzheimer's disease (AD) treatments are limited, offering benefits only in early stages.
• Amyloid-beta (Aβ) peptide reduction strategies have largely failed to halt cognitive decline.
• Neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau, correlate with dementia severity, suggesting tau aggregation as a therapeutic target.

Purpose of the Study:

• To develop novel inhibitors targeting protein kinases involved in tau hyperphosphorylation.
• To investigate the efficacy of these inhibitors in reducing tau phosphorylation and aggregation.
• To identify kinase targets crucial for halting neurodegeneration in Alzheimer's disease.

Main Methods:

• Development of novel inhibitors for glycogen synthase kinase-3 beta (gsk-3β), cyclin-dependent kinase 5 (cdk5), and cyclin-dependent kinase 1 (cdk1).
• Assay of inhibitor activity on tau phosphorylation and tau-tau interactions in cellular models.
• Evaluation of inhibitor effects on the nucleation stage of tau aggregation.

Main Results:

• Inhibitors demonstrated activity in reducing tau phosphorylation and aggregation.
• Compounds affecting all three kinases (gsk-3β, cdk5, cdk1) showed the most significant effects.
• Potent inhibition was observed in the nanomolar range, particularly for inhibitors targeting gsk-3β.

Conclusions:

• Targeting tau aggregation through kinase inhibition is a viable therapeutic strategy for Alzheimer's disease.
• Inhibitors with multi-kinase inhibitory profiles, especially against gsk-3β, show strong potential for AD treatment.
• Further development of these inhibitors could lead to more effective therapies for halting cognitive deterioration in AD patients.